Genomic Health (GHDX) Posts Quarterly Results
Genomic Health (NASDAQ:GHDX) released its earnings data on Tuesday. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.03) by $0.27, Stock Ratings Network.com reports. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $69.20 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. The company’s quarterly revenue was up 13.9% on a year-over-year basis. Genomic Health updated its FY14 guidance to ($0.95)-(0.75) EPS.
Genomic Health (NASDAQ:GHDX) traded up 1.94% on Tuesday, hitting $29.50. 210,015 shares of the company’s stock traded hands. Genomic Health has a one year low of $26.25 and a one year high of $38.99. The stock’s 50-day moving average is $30.26 and its 200-day moving average is $32.09. The company’s market cap is $906.8 million.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note to investors on Thursday, December 26th. They now have a $31.00 price target on the stock. On a related note, analysts at BMO Capital Markets raised their price target on shares of Genomic Health from $18.00 to $20.00 in a research note to investors on Thursday, November 7th. They now have an “underperform” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Genomic Health from $35.00 to $33.00 in a research note to investors on Wednesday, November 6th. They now have a “hold” rating on the stock. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $33.60.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.